Investigating how a specific enzyme influences the transformation of blood cancer.
Official title: Project 3: Role of stromal cell-activated CNOT6L deadenylase in driving AML transformation
Funded at Columbia University Health Sciences · NIH-10935671 · Data updated 2026-11-12
This study is looking at how a specific enzyme called CNOT6L might play a role in the development of acute myeloid leukemia from a related condition called myelodysplastic syndromes, and it aims to find out if changing the levels of this enzyme could help improve treatment options for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 13, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $594,718 |
| NIH project number | 1P01CA285250-01A1 |
| Project ID | NIH-10935671 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with myelodysplastic syndromes who are at risk of developing acute myeloid leukemia.
✕Less likely to help
Patients with other types of blood cancers or those without myelodysplastic syndromes may not benefit from this research.
What this research studies
This research explores the role of the CNOT6L deadenylase enzyme in the development of acute myeloid leukemia (AML) from myelodysplastic syndromes (MDS). It focuses on how the bone marrow's stromal microenvironment contributes to the progression of these blood cancers. By using models and patient samples, the study aims to understand the mechanisms behind AML transformation and how manipulating CNOT6L levels can affect disease outcomes. Patients may benefit from insights that could lead to new treatment strategies targeting this enzyme.
Why it matters
Potential benefit: If successful, this research could lead to novel therapies that prevent or reverse the progression of AML in patients with MDS.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in blood cancers, indicating potential for success in this approach.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Kousteni, Stavroula — Columbia University Health Sciences
- Study coordinator: Kousteni, Stavroula
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.